SCHEDULE: QHSLab, Inc. - Marvin Smollar Family Trust Discloses 14.8% Stake
Schedule 13D
Marvin Smollar Family Trust files Schedule 13D, reporting beneficial ownership of 2,226,280 shares of QHSLab, Inc. common stock, representing 14.8% of the outstanding shares.
Summary
- The Marvin Smollar Family Trust (the "Trust") has filed a Schedule 13D, reporting beneficial ownership of 2,226,280 shares of QHSLab, Inc. common stock.
- This holding represents approximately 14.8% of the total outstanding shares of QHSLab, Inc. common stock, based on 15,032,788 shares outstanding as of March 30, 2026.
- The Trust acquired these shares through three separate transactions, with the first two tranches originally received by Marvin Smollar and later transferred to the Trust, and the third tranche received directly by the Trust.
- The filing acknowledges that applicable filing deadlines were not met, and this statement is being filed on a late basis.
- The Trust holds these shares for estate administration purposes and intends to distribute them according to the Trust instrument and estate administration procedures.
Sentiment
Score: 4
Explanation: StockSavvy.ai views this filing as having a neutral to slightly negative sentiment due to the late submission and the stated intention to distribute shares, which could increase selling pressure.
Positives
- The Marvin Smollar Family Trust holds a significant stake of 14.8% in QHSLab, Inc., indicating substantial prior investment or involvement.
- The shares were acquired through various transactions, including distributions from MedScience Research Group, Inc. and conversion of a promissory note, suggesting a history of business dealings related to the company.
Negatives
- The filing is being submitted on a late basis, indicating a failure to meet previous SEC filing deadlines.
- The Trust's stated intention is to distribute all shares, which could lead to increased selling pressure on the stock if not managed carefully.
Risks
- The Trust intends to distribute all 2,226,280 shares of Common Stock pursuant to the terms of the Trust instrument and applicable estate administration procedures, which could lead to increased selling pressure on the stock.
- The shares received on January 29, 2026, are subject to Rule 144 restrictions, which may impact the timing and manner of their sale.
Future Outlook
The Trust intends to distribute all 2,226,280 shares of Common Stock pursuant to the terms of the Trust instrument and applicable estate administration procedures. These shares are subject to Rule 144 restrictions.
Management Comments
- The Trust holds shares solely for purpose of estate administration.
- The Trust intends to distribute all 2,226,280 shares of Common Stock pursuant to the terms of the Trust instrument and applicable estate administration procedures.
Industry Context
StockSavvy.ai notes that Schedule 13D filings typically signal a significant ownership stake, often by an activist investor or a party with a strategic interest. In this case, the filing by a family trust for estate administration purposes suggests a passive holding that may eventually lead to liquidation, potentially impacting share supply.
Stakeholder Impact
- Shareholders: Potential for increased selling pressure on the stock as the Trust distributes its shares.
- Creditors: No direct impact mentioned.
- Employees: No direct impact mentioned.
- Suppliers: No direct impact mentioned.
- Customers: No direct impact mentioned.
Next Steps
- Distribution of all 2,226,280 shares of Common Stock by the Trust according to its instrument and estate administration procedures.
Key Dates
| Date | Description |
|---|---|
| 2019-12-27 | Date of original issuance of the 10% convertible promissory note. |
| 2021-03-15 | Date of Convertible Note Assignment Agreement and direction for conversion of the Note. |
| 2021-06-29 | Date of issuance of 584,079 shares of Common Stock as a pro-rata distribution from MedScience Research Group, Inc. |
| 2021-09-28 | Date of issuance of 181,313 shares of Common Stock upon conversion of the promissory note. |
| 2023-02-13 | Date of the Marvin Smollar Family Trust. |
| 2025-11-27 | Date of death of grantor Marvin Smollar, upon which the Trust became irrevocable. |
| 2025-12-31 | Date as of which principal and accrued interest on a promissory note to MedScience totaled approximately $470,529. |
| 2026-01-29 | Date the Trust received 1,460,888 shares of Common Stock as a pro-rata distribution from MedScience Research Group, Inc. |
| 2026-03-30 | Date as of which there were 15,032,788 shares of Common Stock outstanding. |
| 2026-03-31 | Date of Issuer's Annual Report on Form 10-K filing. |
| 2026-04-27 | Date of the Schedule 13D filing. |
| 2026-01-29 | Date of QHSLab's Form 8-K filing reporting the issuance of shares to MedScience. |
Recommendation
holdThe filing indicates a significant ownership stake but also a stated intention to distribute shares, suggesting potential future selling pressure. The late filing raises concerns about compliance. Without further information on the Trust's distribution strategy or QHSLab's operational performance, a 'hold' recommendation is prudent, allowing investors to monitor the situation.
Keywords
QHSLab, Inc., Schedule 13D, Marvin Smollar Family Trust, Beneficial Ownership, Common Stock, SEC Filing, Estate Administration, Rule 144
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.